GHRP-2 5mg
Synthetic hexapeptide secretagogue studied for pulsatile growth hormone induction via ghrelin receptor pathway agonism.
Mechanism
Acts as an agonist at the pituitary GHS-R1a (ghrelin) receptor to trigger dose-dependent, pulsatile release of endogenous growth hormone.
Dosing
Published research regimens initiate evaluation at 100 mcg administered once daily on an empty stomach.
Reconstitution
Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 1.67 mg/mL (1,667 mcg/mL).
Storage
Keep unmixed lyophilized vials frozen at -20 °C, and store reconstituted solutions under refrigeration between 2 and 8 °C protected from light without refreezing.
Mix & measure GHRP-2 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure GHRP-2 5mg
Vial strength → BAC water → target dose
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (1× daily) | ~6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg (1× daily) | ~9 units (0.09 mL) |
| Weeks 5–8 | 200 mcg (1× daily) | ~12 units (0.12 mL) |
| Weeks 9–16 | 200–300 mcg (1× daily) | ~12–18 units (0.12–0.18 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water using a sterile syringe.
- 2
Introduce the bacteriostatic water slowly along the inner glass wall of the 5 mg GHRP-2 vial to minimize agitation.
- 3
Gently roll or swirl the vial until the lyophilized cake fully dissolves, avoiding vigorous shaking.
- 4
Clearly label the vial with the preparation date and resulting concentration, then store it refrigerated at 2–8 °C.
Supplies Needed
Peptide Vial
Lyophilized GHRP-2 (5 mg) container providing the active research compound.
Insulin Syringes (U-100)
Calibrated 1 mL syringes utilized for precise measurement of low microgram volumes.
Bacteriostatic Water
Sterile diluent (3.0 mL required per vial) containing benzyl alcohol to reconstitute the peptide.
Alcohol Swabs
Used to sanitize the vial rubber stopper and test site surfaces prior to handling.
Why researchers study it
GH & IGF-1 support
Appetite stimulation
Body composition & lipolysis
Sleep architecture
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide classified as a growth hormone secretagogue. In laboratory models, it selectively targets and binds the growth hormone secretagogue receptor (GHS-R1a), which replicates the signaling cascades naturally regulated by the hunger hormone ghrelin. Investigational literature frequently explores this peptide to evaluate its potential to stimulate the anterior pituitary gland to release endogenous somatotropin. Unlike certain second-generation counterparts that demonstrate absolute selectivity, GHRP-2 displays a secondary biological profile characterized by minor elevations in circulating levels of cortisol and prolactin. Because of this neuroendocrine signature, researchers often evaluate its downstream behavior both independently and in conjunction with growth hormone-releasing hormone (GHRH) analogues to assess synergistic hormone modulation. All experimental evaluations must observe that GHRP-2 is restricted to preclinical scientific investigation. It is not approved for therapeutic administration, and documented literature highlights that daily timing must account for biological down-regulation and receptor tachyphylaxis resulting from excessive exposure.
References
- 1.Domestic Animal Endocrinology, Year not stated — Effects of GHRP-2 on growth hormone release and growth performance, illustrating ghrelin-receptor activation
- 2.J Clin Endocrinol Metab, Year not stated — Eight-month treatment with graded doses of GHRP-2 in GH-deficient children: sustained GH/IGF-1 response
- 3.Eur J Endocrinol, Year not stated — Five-day daily subcutaneous GHRP-2 in healthy young men: response attenuation and IGF-I effects
- 4.Endocrine, Year not stated — GH/IGF-1 response to acute and chronic GHRP-2, GHRH(1-44) and their combination in older adults
- 5.American Journal of Men’s Health, Year not stated — Growth-hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels
- 6.Sexual Medicine Reviews, Year not stated — The safety and efficacy of growth-hormone secretagogues: a comprehensive review
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.